Article Text

Download PDFPDF
EP1295 Primary vaginal Non-Hodgkin´s lymphoma: a case report of a rare entity
  1. O Ferreira Rangel Neto,
  2. LM Martins,
  3. MGF Sartori,
  4. MGBK Uyeda and
  5. MJBC Girão
  1. Gynecology Department, Federal University of Sao Paulo, Paulista School of Medicine, São Paulo, Brazil


Introduction/Background The female genital tract may be affected by Non-Hodgkin lymphoma in about 30%, most due to secondary systemic involvement. Primary lymphoma of gynaecological tract is an extremely rare entity, comprising 0.2–1.1% of all cases of extra nodal lymphoma. Primary vaginal Non-Hodgkin lymphoma (PVNHL) accounts for less than 0.1%. PVNHL is most often presented as solid consistency mass of defined limits. It may also infiltrate subcutaneous tissue and infiltrate deep fat tissue. Patients may also present abnormal vaginal bleeding, dyspareunia, vaginal discharge, and irritative urinary symptoms.

Methodology This is a case report of a young woman whose diagnosis of PVNHL came after symptoms of genital discomfort and the presentation of vulvar mass of progressive enlargement.

Results Woman, 32 years old, that initially presented with urinary symptoms. After a few weeks a large vaginal mass appeared, and a sampling of tissue was performed. The histological diagnosis of a Non-Hodgkin’s lymphoma of the vagina (diffuse large B-cell lymphoma) was made. After 6 cycles of R-CHOP chemotherapy (Rituximab, Endoxan, Doxorrubicina, Predinisone) there were full regression of symptoms and involution of vulvar mass. Patient were under follow up without evidence of relapse.

Conclusion The diagnosis of PVNHL is very difficult for several reasons: First because of this rarity, after the similarity with day-to-day gynecological symptoms and other more commons affections that involves vaginal discomfort and pain. The PVNHL management is challenging and remains unclear due to the lack of specific guideline protocols. Therefore, a multimodal treatment is usually the approach which involves association of surgery and chemo and radiotherapy.

Disclosure Nothing to disclose

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.